Log In
BCIQ
Print this Print this
 

Staccato loxapine (AZ-104)

  Manage Alerts
Collapse Summary General Information
Company Grupo Ferrer Internacional S.A.
DescriptionLow-dose loxapine delivered via Staccato system inhaler
Molecular Target Dopamine D2 receptor ; Serotonin (5-HT2) receptor
Mechanism of ActionDopamine D2 receptor antagonist; Serotonin (5-HT2) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMigraine
Indication DetailsTreat migraine
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$54.6M

$19.6M

$35.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/21/2016

$54.6M

$19.6M

$35.0M

Get a free BioCentury trial today